Derui is invested and controlled by Fade Biotechnology Pharmaceutical Co., Ltd. It is a Taiwanese pharmaceutical company mainly engaged in research and development of pharmaceutical formulation technology.

China Resources Sanjiu Medical & Pharmaceutical CO., LTD.

Shenzhen Kangtai Biological Products Co., Ltd. is a listed enterprise integrating research, development, production and sales of biological products, stock code 300601. Headquartered in Shenzhen, the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.

​Shenzhen Salubris Pharmaceuticals Co., Ltd. was established in November 1998, mainly producing and operating chemical raw materials, powder injections, tablets, capsules and other products. It is a high-tech joint venture enterprise that integrates research and development, production, and sales. The company was one of the first enterprises to be awarded the "Integrity Golden Ding" and "Shenzhen Top 100 Commercial Super Brand", and has been recognized as a "Shenzhen High tech Enterprise" and "Shenzhen Foreign Investment Advanced Technology Enterprise".

Jiangxi Bioman Pharmaceutical Co., Ltd. was founded in 2010 and is an innovative technology company specializing in the research, development, and production of active pharmaceutical ingredients and pharmaceutical intermediates. The company is technology oriented, regards quality as its life, and takes customer needs as its responsibility. From customer customization to large-scale production, from technology to documentation, from laboratory to GMP management, the company provides customers with comprehensive services.

Guilin Pavay Biotechnology Co., Ltd. was founded in October 2015 and is a technology-based enterprise specializing in the research and production of products such as epidermal growth factor and sodium hyaluronate. As a professional manufacturer of medical beauty products, Warnover has multiple production lines, including pre filled syringe filling production line, aluminum tube filling production line, plastic bottle filling production line, and a batch of advanced production and testing equipment. In the process of years of enterprise development, the company has established a mature medical beauty market channel.

Hairui Pharmaceutical is a modern comprehensive pharmaceutical enterprise integrating R&D, production and marketing. It is located in Science City, Guangzhou High-tech Industrial Development Zone. It currently has 2 drug research institutes, 4 modern production workshops and 1 Automated high-bay warehouse.

BGI Genomics is the world's leading integrated solutions provider of precision medicine, now serving customers in more than 100 countries, involving over 2,300 medical institutions.

Shenzhen Xinguang United Pharmaceutical Co., Ltd. mainly engages in the production of Banlangen tea, production of Hantao leaves, production of Xiasangju granules and other products. The company respects the corporate spirit of "down-to-earth, hard work, and responsibility", and with integrity, win-win, and innovative business philosophy, creates a good corporate environment. With a new management model, perfect technology, thoughtful service, and excellent quality as the foundation of survival, we always adhere to the principle of putting customers first and serving them wholeheartedly, and insist on using our own services to impress customers.

Shenzhen Heshun Tang Pharmaceutical Co., Ltd. is the first privately-owned chain medical institution in China to focus on the operation of high-quality traditional Chinese medicine and promote the implementation of the "Famous Doctors, Famous Drugs, Famous Stores" and "3+1" traditional Chinese medicine services of famous factories. It has become a shining example of the traditional Chinese medicine industry in Shenzhen.

Hong Kong Baomingtang International Group Co., Ltd. was founded in the eighth year of Xianfeng, 1858 AD, with a history of over 100 years. The company's headquarters is located in Shenzhen, China. Shenzhen Baomingtang Health Products Co., Ltd. was established in June 1998. At present, more than 100 branches and specialty stores have been established in major and medium-sized cities across China, including Beijing, Shanghai, East China, South China, and Guangdong;

Shenzhen Tianneng Pharmaceutical Co., Ltd. is located in the Tianneng Science and Technology Park in Pingdi Street, Longgang District, Shenzhen, with beautiful scenery, pleasant climate, lush trees, and convenient transportation; Having a spacious, bright, and tidy garden style factory, covering an area of 12000 square meters, including a building area of 17000 square meters, the environment is beautiful, and it is a teaching, research, and internship base for medical universities. Currently, the industrial scale is constantly expanding.

Hanhai Gene is committed to significantly reducing the cost of genetic testing and providing high-quality genetic testing services. At present, the third-generation single-molecule direct sequencing technology has been successfully developed. This technology can greatly simplify the gene detection process, reduce sequencing costs and detection cycles by directly reading DNA and RNA information in blood or tissue.

Guangdong Wuzhou Pharmaceutical Co., Ltd. is a high-tech enterprise in Guangdong Province, a private technology enterprise in Guangdong Province, a national drug GMP certified enterprise, and an ISO9001:2000 quality management system certified enterprise; The company's "Tianqiao Brand" trademark is a well-known trademark in Guangdong Province;

Jiangxi Longlai Biopharmaceutical Co., Ltd. was founded in 2009 by Dr. Wu Shengwen, a renowned overseas expert who returned to China. It was completed in 2011 and merged with the American company Kairuist (Suzhou) Biochemical Co., Ltd. at the end of 2012. Currently, Dr. Wu Shengwen serves as the President of the merged new company and also serves as the Chairman and General Manager of Longlai Company. The company is led by internationally renowned investment bank Kaipeng Huaying from the United States, with other investors including Israel, Hong Kong, Japan, Suzhou, and Jiangxi Venture Capital. The company invested 100 million yuan in personnel in the early stage

Zhongke Hongji Biotechnology Co., Ltd. was established on April 14, 2010, with a registered capital of RMB 500 million. Its business scope is the research, development, and sales of biotechnology products. The company's construction adheres to the requirements of industrialization, agglomeration, and international development, adhering to the combination of expanding industrial scale and enhancing independent innovation capabilities, in order to accelerate the development of industries such as biopharmaceuticals, bio based chemicals, biomaterials, biological manufacturing, and biological environmental protection.

Boji Medical Technology Co., Ltd(known as Boji biomedicals with the stock code of 300404) was founded in 2002 and listed on Shenzhen GEM in 2015. Boji is a new high-tech enterprise(CRO+CDMO) that provides one-stop service for domestic and abroad pharmaceutical enterprises, such as the R&D of drugs, medical devices and health products. Headquartered in the wisdom city of Tianhe District in Guangzhou, the company has gathered nearly 100 biomedical R&D talents and registered legislative experts with an area of nearly 3000 square meters. The company owns 9 wholly-owned subsidiaries with different business and more than 10 holding and shareholding companies.

Guangdong Jiaying Pharmaceutical Co., Ltd. was established in March 2003 through the restructuring of Meizhou Pharmaceutical Factory. In December 2007, the company's shares were successfully listed on the Shenzhen Stock Exchange, with a total assets of 245 million yuan and a net asset of 213 million yuan. It is a diversified listed company and high-tech enterprise focusing on the research, development, production and sales of patent drugs. Jiaying Pharmaceutical has a large modern production base for traditional Chinese patent medicines and simple preparations production, with a total investment of 180 million yuan. The new R&D and production base covers an area of 55000 square meters, with a total construction area of 80000 square meters